Increased Serum Levels of soluble ST2 as a Predictor of Disease Progression in Systemic Sclerosis.

Günther, F; Straub, R H; Hartung, W; Luchner, A; Fleck, M; Ehrenstein, B

Günther, F; Straub, R H; Hartung, W; Luchner, A; Fleck, M; Ehrenstein, B.

Afiliação

Günther F; Department of Rheumatology and Clinical Immunology, Asklepios Clinic, Bad Abbach, Germany.
Straub RH; Department of Internal Medicine I, University Medical Center, Regensburg, Germany.
Hartung W; Department of Rheumatology and Clinical Immunology, Asklepios Clinic, Bad Abbach, Germany.
Luchner A; Department of Cardiology, Barmherzige Brüder Hospital, Regensburg, Germany.
Fleck M; Department of Rheumatology and Clinical Immunology, Asklepios Clinic, Bad Abbach, Germany.
Ehrenstein B; Department of Internal Medicine I, University Medical Center, Regensburg, Germany.

Scand J Rheumatol ; 51(4): 315-322, 2022 07.

Article em En | MEDLINE | ID: mdl-34474647

Assuntos

Interleucina-33; Escleroderma Sistêmico; Biomarcadores; Progressão da Doença; Humanos; Proteína 1 Semelhante a Receptor de Interleucina-1; Prognóstico; Curva ROC; Escleroderma Sistêmico/diagnóstico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Interleucina-33 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Scand J Rheumatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google